Roche and Hycor Biomedical Sign Global Distribution Agreement

Published: May 17, 2012

INDIANAPOLIS, May 16, 2012 /PRNewswire/ -- HYCOR Biomedical, Inc., a leading manufacturer of diagnostic products, and Roche today announced the signing of a global distribution agreement of KOVA® urinalysis products. As part of the agreement, Roche will distribute KOVA urinalysis plastics and controls products with its urinalysis tests and platforms worldwide for the next five years.

"Concurrent with our global leading position in invitro diagnostics, the expanded agreement with HYCOR emphasizes our commitment of bringing industry expertise in providing high-quality urinalysis products to health professionals at hospital laboratories," said Colin Brown, Head of Roche Professional Diagnostics.

KOVA urinalysis controls are used to validate the performance of urine chemistry test strips and readers and to help focus microscopic sediment analysis. KOVA urinalysis controls are part of a complete line of urinalysis products that include specially engineered Glasstic slides and high quality sample tubes.

"KOVA has been an industry-leader for more than 30 years, and we are pleased to partner with Roche to distribute this group of quality urinalysis products worldwide," said Dick Aderman, President and CEO, HYCOR. "This agreement allows us to expand our presence into an additional 85 markets, further underscoring the value it brings to the healthcare professionals and patients it serves."

All KOVA products are designed to make it easy and cost-efficient to standardize the urinalysis procedure by ensuring consistent sample preparation.

About HYCOR Biomedical, Inc.
Founded in 1981, HYCOR is a global manufacturer and marketer of in vitro diagnostics products. Since its founding, HYCOR has expanded its presence into urinalysis, allergy and autoimmune products used in clinical laboratories, hospitals and doctors' offices worldwide. Among its products, HYCOR markets the HYTEC, KOVA® and AUTOSTAT brands. The company is focused on delivering products that provide the highest value to clinicians through innovation, reliability and customer service. For more information, please visit

About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information:

SOURCE HYCOR Biomedical, Inc.

Back to news